267 related articles for article (PubMed ID: 16643483)
1. alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
Paick JS; Ku JH; Shin JW; Yang JH; Kim SW
BJU Int; 2006 May; 97(5):1017-23. PubMed ID: 16643483
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study.
Cho MC; Ku JH; Paick JS
Urology; 2009 Mar; 73(3):549-53; discussion 554-5. PubMed ID: 19100605
[TBL] [Abstract][Full Text] [Related]
5. Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.
Song YS; Ku JH
Int Urol Nephrol; 2007; 39(4):1147-52. PubMed ID: 17610040
[TBL] [Abstract][Full Text] [Related]
6. Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
Ku JH; Um JM; Shin JW; Yang JH; Paick JS
Urology; 2006 May; 67(5):978-83. PubMed ID: 16698358
[TBL] [Abstract][Full Text] [Related]
7. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
[TBL] [Abstract][Full Text] [Related]
8. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
Zhang K; Yu W; Jin J; Ye H; Wang X; Zhang N; Yang Y; Zhong C; Wan B
Urology; 2011 Sep; 78(3):636-40. PubMed ID: 21696807
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
[TBL] [Abstract][Full Text] [Related]
12. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
Low BY; Liong ML; Yuen KH; Chee C; Leong WS; Chong WL; Khan NA; Cheah PY; Liong KK
J Urol; 2008 Apr; 179(4):1461-9. PubMed ID: 18295277
[TBL] [Abstract][Full Text] [Related]
13. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
14. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
[TBL] [Abstract][Full Text] [Related]
16. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
[TBL] [Abstract][Full Text] [Related]
17. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
19. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures.
Yap TL; Brown C; Cromwell DA; van der Meulen J; Emberton M
BJU Int; 2009 Oct; 104(8):1104-8. PubMed ID: 19485993
[TBL] [Abstract][Full Text] [Related]
20. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]